Cookies used for improved website experience

Siemens Healthineers and our partners use cookies and other similar technologies to operate the Siemens Healthineers websites and personalize content and ads. You may find out more about how we use cookies by clicking "Show details" or by referring to our Cookie Policy.
You may allow all cookies or select them individually. And you may change your consent and cookie preferences anytime by clicking on the "Review and change your consent" button on the Cookie Policy page.

Serum amyloid A (SAA) as a predictive marker for severity and morbidity from COVID-19

Dr. Pouw explores the relevance and value of serum amyloid A (SAA) and other inflammation markers in the management of hospitalized COVID-19 patients. The impact of the evolving SARS-CoV-2 variants as well as the degree of progression of COVID-19 on inflammation markers and patient management are analyzed and reviewed.

Nadine Pouw, Franciscus, Gasthuis & Vlietland

Dr. Nadine Pouw
Franciscus, Gasthuis & Vlietland
Netherlands